Who are Alumis's investors?

Alumis's investors include Foresite Capital, HBM Healthcare Investments, HBM Partners, Nextech Invest, OrbiMed, Samsara BioCapital, SR One Capital Management, venBio Partners and 2 more.

How much funding has Alumis raised?

Alumis has disclosed $345.1M raised across 1 round.

Where is Alumis headquartered?

Alumis is headquartered in South San Francisco, US.

Alumis

NASDAQ: ALMS

South San Francisco, US · Founded 2021 · 262 employees on LinkedIn · 10 known investors

Find your way into Alumis

661 people in our graph share verified history with the Alumis team — schools, employers, funds. One of them is your warm intro.

Pamela Kleinunlockedknows Martin Babler · together at Sardona Therapeutics (overlapped)

knows the team · via Sardona Therapeutics

×2knows the team · via Ventyx Biosciences

×2knows the team · via Principia Biopharma

knows the team · via Horizon

knows the team · via Theravance Biopharma

Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.

AI & Machine Learning Biotech Digital Health Healthtech Longevity

Founders & leadership

Martin Babler President, Chief Executive Officer and Chairman of the BoardHe has served on the boards of Prelude Therapeutics since 2021, 89bio from 2024 to 2025, and as chairman of the board of Sardona Therapeutics from 2021 to 2025. He has also been a co-owner of Paradigm Ranch Management LLC since 2008.

Mark BradleyChief Development Officer

Kolbot BySVP, Head of Technical Operations

Jack Danilkowicz Chief Commercial OfficerChief Commercial Officer at Alumis, a clinical-stage biopharmaceutical company. Jack has experience in sales, marketing, operations, and business development.

Jörn Drappa Chief Medical OfficerJörn Drappa is Chief Medical Officer of Alumis, a clinical-stage biopharmaceutical company developing targeted therapies for immune-mediated diseases. He is a board-certified internist and rheumatologist with 30 years of research and clinical experience, including 19 years in pharmaceutical and biotech industry roles involving small and large molecule development across phases I–III in asthma, COPD, systemic lupus erythematosus, dermatological, cardiovascular, and orphan disease programs.

David M GoldsteinChief Scientific Officer

Grace HaltehSVP, Head of Quality and Regulatory

Roy HardimanChief Business and Strategy Officer

Claire Langrish SVP, Head of Immunology and Translational ScienceClaire Langrish is an immunologist and drug discoverer serving as SVP and Head of Immunology and Translational Science at Alumis, where she leads preclinical and clinical translation efforts in immunology. Her research has focused on immune-mediated disease mechanisms and drug development.

Sanam PangaliChief Legal Officer and Corporate Secretary

John SchroerChief Financial Officer

David M. GoldsteinChief Scientific Officer

Investors · 10

Foresite Capitallisted by Foresite CapitalWest Hollywood

How we know: Foresite Capital's portfolio page · the S-1 prospectus · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us

HBM Healthcare Investmentslisted by HBM Healthcare InvestmentsZug

How we know: HBM Healthcare Investments's portfolio page · Not right? Tell us

HBM Partnerslisted by HBM PartnersZug · $5M – $50M

How we know: HBM Partners's portfolio page · Not right? Tell us

Nextech Investlisted by Nextech InvestZurich · $648K – $3.2M

How we know: Nextech Invest's portfolio page · Not right? Tell us

OrbiMedlisted by OrbiMedNew York · $1M – $75M

How we know: OrbiMed's portfolio page · the VCSheet dataset · Not right? Tell us

Samsara BioCapitallisted by Samsara BioCapitalMenlo Park

How we know: Samsara BioCapital's portfolio page · the S-1 prospectus · Not right? Tell us

SR One Capital Managementlisted by SR One Capital ManagementRedwood City

How we know: SR One Capital Management's portfolio page · Not right? Tell us

venBio Partnerslisted by venBio PartnersSan Francisco

How we know: a partner's Signal profile · the VCSheet dataset · Not right? Tell us

Westlake Village BioPartnerslisted by Westlake Village BioPartnersLos Angeles · $100K – $5M

How we know: Westlake Village BioPartners's portfolio page · the VCSheet dataset · Not right? Tell us

venBio Global StrategicinferredSan Francisco

How we know: board seat on SEC Form D · Not right? Tell us

Funding

SEC filings, press & company announcements

$345.1M disclosed across 1 round · 2026

$345.1Mpublic offeringJan 2026 · 2 sources
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Valuation · disclosed

Disclosed events

$830.5Mvaluation at IPOJun 2024 · $16.00/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Competitors · 3

by search overlap

Eli Lilly132 shared keywordsEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.

Exelixis129 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.

IQVIA110 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.

Companies competing with Alumis for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Alumis do?: Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
Who are Alumis's investors?: Alumis's investors include Foresite Capital, HBM Healthcare Investments, HBM Partners, Nextech Invest, OrbiMed, Samsara BioCapital, SR One Capital Management, venBio Partners and 2 more.
How much funding has Alumis raised?: Alumis has disclosed $345.1M raised across 1 round.
Where is Alumis headquartered?: Alumis is headquartered in South San Francisco, US.